Synapse - Department of Medicine

Results (39616)

Impact of response to hypomethylating agent-based therapy on survival outcomes in the context of baseline clinical-molecular risk and transplant status in patients with myelodysplastic syndromes/neoplasms (MDS): An analysis from the international consortium for MDS (icMDS) validate database

Meeting Abstract

Rolles, B.; Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stempel, J. M.; Lanino, L.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
Blood (2024)

Fulltext@MSK | Save

Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients

Meeting Abstract

El Chaer, F.; Rein, L. A. M.; Yuda, J.; Shimoda, K.; Takami, A.; Ichii, M.; McCloskey, J.; Scandura, J. M.; Iurlo, A.; Bose, P.; more...
Blood (2024)

Fulltext@MSK | Save

CDI9-CD28 (RO7443904) combination with glofitamab enhances T-cell proliferation and effector function in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Meeting Abstract

Korfi, K.; Wilson, S.; Jiang, Z.; Christiansen, A.; Krishnan, S.; Jamois, C.; Blank, A.; Epp, A.; Silva, A.; Knuckles, P.; more...
Blood (2024)

Fulltext@MSK | Save

Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment

Meeting Abstract

DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
Blood (2024)

Fulltext@MSK | Save

Final analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma

Meeting Abstract

Diefenbach, C. S.; Zelenetz, A. D.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Leung, W.; more...
Blood (2024)

Fulltext@MSK | Save

Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: Long-term results from the EPCORE NHL-2 trial

Meeting Abstract

Falchi, L.; Offner, F.; de Vos, S.; Brody, J.; Cordoba, R.; Linton, K.; Snauwaert, S.; Clausen, M. R.; Oki, T.; Steele, A. J.; more...
Blood (2024)

Fulltext@MSK | Save

Improving outcomes in plasmablastic lymphoma: A multicenter experience from an American cohort

Meeting Abstract

Hamby, M.; Egleston, B.; Frosch, Z. A. K.; Steiner, R. E.; Noy, A.; Carvajal, V.; Tolu, S. S.; Jean-Louis, G.; Amengual, J. E.; Patel, R.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Meeting Abstract

Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
Blood (2024)

Fulltext@MSK | Save

ABBV-383 plus daratumumab-dexamethasone in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Meeting Abstract

Rodriguez, C.; Mielnik, M.; Kazandjian, D.; Janowski, W.; Low, M. S. Y.; Pianko, M.; Yuda, J.; Van Der Weyden, C.; Anderson, L. D. Jr; Banerjee, R.; more...
Blood (2024)

Fulltext@MSK | Save

Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI)

Meeting Abstract

Atallah, E. L.; Levy, M. Y.; Koller, P. B.; Sasaki, K.; Tantravahi, S. K.; Andorsky, D.; Bremer, C. T.; Zeidner, J. F.; Luskin, M. R.; Munker, R.; more...
Blood (2024)

Fulltext@MSK | Save